Disclosed are di-substituted amide compounds of formula I, wherein the substituents are as described within the specification. Examples of compounds of formula I include: N-Cyclohexyl-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide and trans-4-[(2,1,3-Benzoxadiazol-5-ylcarbonyl)(methyl)amino]cyclohexyl N,N-dimethyl glycinate hydrochloride. Further disclosed is a pharmaceutical composition comprising an effective amount of a compound of formula I, and the use of a compound of formula I in the manufacture of a medicament for use in the treatment of a glutamatergic condition, memory or other cognitive impairments, schizophrenia, Parkinsons disease, ADHD, Rett Syndrome, respiratory depression, breathing-related sleep disorders or sleep apnea, Fragile-X Syndrome, Alzheimers disease.
